Search
Search Results
-
Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours
BackgroundEzabenlimab (BI 754091) is a humanised monoclonal antibody targeting programmed cell death protein-1. We report results from open-label,...
-
Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors
PurposeThis two-part, open-label, non-randomized dose-escalation study aimed to define the maximum tolerated dose (MTD) of BI 836880 (humanized...
-
Immuntherapie gegen Gliome
BackgroundGliomas represent the most frequent malignant primary brain tumors in adults. Despite multimodal treatment concepts involving surgery,...
-
89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
PurposeAlthough lymphocyte activation gene-3 (LAG-3) directed therapies demonstrate promising clinical anti-cancer activity, only a subset of...
-
Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis
BackgroundHepatocellular carcinoma (HCC) is one of the cancers with the highest morbidity and mortality. Sorafenib used to be the main treatment for...
-
Immunological Checkpoint Blockade in Anal Squamous Cell Carcinoma: Dramatic Responses Tempered By Frequent Resistance
Abstract Purpose of ReviewSquamous cell carcinoma of the anus (SCCA) is an HPV-associated malignancy that has limited treatment options....
-
The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy
Purpose of ReviewNew therapies are needed to potentiate the effects of current immunotherapies and overcome resistance. The stimulator of interferon...
-
ImmunoPET provides a novel way to visualize the CD103+ tissue-resident memory T cell to predict the response of immune checkpoint inhibitors
BackgroundImmune checkpoint inhibitors (ICIs) have made significant progress in oncotherapy improving survival of patients. However, the benefits are...
-
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surgery, radiation,...
-
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Immunotherapy represented by anti-PD-(L)1 and anti-CTLA-4 inhibitors has revolutionized cancer treatment, but challenges related to resistance and...
-
Emerging phagocytosis checkpoints in cancer immunotherapy
Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the adoptive transfer of engineered immune cells, has revolutionized...
-
Exploiting RIG-I-like receptor pathway for cancer immunotherapy
RIG-I-like receptors (RLRs) are intracellular pattern recognition receptors that detect viral or bacterial infection and induce host innate immune...
-
Clinical relevance of tumour-associated macrophages
In the past decade, substantial advances have been made in understanding the biology of tumour-associated macrophages (TAMs), and their clinical...
-
Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy
Since the discovery of Stimulator of Interferon Genes (STING) as an important pivot for cytosolic DNA sensation and interferon (IFN) induction,...
